Aptamers Market

Aptamers Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    173

  • Pages
    294

  • View Count
    14491

-Most of the aptamer drugs are being developed as RNA-based therapies; 46% of the aptamer-based therapies are in pre-clinical stage and are being developed for various therapeutic areas

Aptamers Market Size Overview

The aptamers market size is estimated to be worth $451 million in 2024 and is expected to reach $12.8 billion by 2035, growing at CAGR of 36% during the forecast period 2024-2035. The new research study consists of industry trends, detailed market analysis, key market insights, market impact analysis, market forecast and opportunity analysis.

Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales (USD 200 million) of the aforementioned product further bolstered the confidence of industry stakeholders in this new therapeutic modality, creating lucrative opportunity for therapy developers.

Aptamers Market Size, by Route of Administration, 2024-2035 (USD Billion)

To learn more about this report, request a free sample copy

Presently, a significant portion of the existing manufacturing capabilities and expertise in aptamers market belongs to more than 50 contract service providers. Therefore, several researchers and therapy / diagnostic developers prefer to outsource their aptamer manufacturing operations. Given the rise in global disease burden over the past few years, there has been an evident increase in the demand for effective targeted therapies along with novel diagnostic approaches to reduce development timelines and investments.

We believe that, with an increase in the number of aptamer-based therapies being developed and subsequent advancement of therapies across various stages of clinical trials, and their eventual commercialization, the opportunities for custom / contract service providers is likely to increase in the foreseen future. Overall, the global aptamers market (comprising aptamer therapeutics, technologies and services) is poised to witness healthy market growth during the forecast period, with pioneers in the field likely to benefit from the first-to-market advantage.

Aptamers Market Report Scope

The market research report presents an in-depth analysis of the various companies that are engaged in the global market of aptamers, across different segments, as defined in the table below:

Global Aptamers Market: Report Attributes / Market Segmentations

Key Report Attribute Details
Historical Trend 2018-2023
Base Year 2023
Forecast Period 2024-2035
Market Size 2024 $451 Million
CAGR 36%
Segment
  • Aptamer Therapeutics
  • Aptamer Technologies
  • Aptamer Services
Application Area
  • Therapeutics
  • Research
  • Diagnostics
Type of Aptamer
  • DNA
  • RNA
  • Peptides
Target Indication
  • Geographic Atrophy
  • Macular Degeneration
  • Von Willebrand Diseases
  • Hemophilia A
Route of Administration
  • Intravitreal
  • Intravenous
  • Subcutaneous
Scale of Operation
  • Small Scale
  • Medium Scale
  • Large Scale
Focus Area
  • Product Development
  • Product Commercialization
  • Technology Integration
  • Technology Utilization
  • Others
Company size
  • Very Small
  • Small
  • Mid-sized
  • Large
  • Very Large
Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Key Companies Profiled
  • Ajinomoto Bio-Pharma Services
  • BioSpring
  • CliniSciences
  • CMIC Group
  • Halo-Bio RNAi Therapeutics
  • LGC Biosearch Technologies
  • NeoNeuro
  • New England Biolabs
  • Nitto Denko Avecia
  • NOXXON Pharma
  • RIBOMIC
  • SomaLogic
(Full list of 170+ companies captured is available in the report)
PowerPoint Presentation
(Complimentary)
Available
Customization Scope 15% Free Customization

Excel Data Packs
(Complimentary)

  • Market Landscape Analysis (Therapeutic Candidates)
  • Market Landscape Analysis (Technology Providers)
  • Market Landscape Analysis (Service Providers)
  • Company Competitiveness Analysis
  • Technology Competitiveness Analysis
  • Product Competitiveness Analysis
  • Partnerships and Collaborations
  • Funding and Investments
  • Grants Analysis
  • Publication Analysis
  • Patent Analysis
  • Start-up  Health Indexing
  • Demand Analysis
  • Market Forecast and Opportunity Analysis


One of the key objectives of this aptamers market report was to estimate the current market size, opportunity and the future market growth potential of this domain in pharmaceutical market, over the forecast period. We have provided an informed estimate on the market evolution during the forecast period 2023-2035.

The market report also features the likely distribution of the current and forecasted opportunity within the aptamers market across various segments, such as Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Aptamers Market: Key Insights

The “Aptamers Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)” market report features an extensive study of the current market landscape, market size, market share, market analysis, market forecast and future opportunities for the aptamers companies involved in the pharmaceutical market. The report highlights the efforts of several drug developers engaged in this rapidly emerging market segment of the pharmaceutical industry. Key takeaways of the aptamers market analysis are briefly discussed below.

Aptamers Market Landscape: Second FDA Approval of Aptamer Therapeutic in 2023 Raising the Hopes

Macugen was the first aptamer therapeutic to receive approval in 2004 for treatment of wet AMD. Administered through an intraocular injection, the drug was later discontinued owing to the availability of competing small molecule VEGF inhibitors. In August 2023, FDA approved the second RNA aptamer, Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration. The drug, earlier known as Zimura, has been developed by Iveric Bio (acquired by Astellas in July 2023). The drug was launched in the US in September 2023 and achieved sales of JPY 5.3 billion in the first nine months of FY 2023.

In addition, post the onset of COVID-19 pandemic, there has been a significant rise in the demand for COVID-19 testing kits, which has prompted several companies to develop aptamer-based diagnostic tools for the detection of SARS-CoV-2. Currently, companies are working on using aptamers for developing diagnostics for various other indications. In February 2024, Aptamer Group partnered with Neuro-Bio to create tests that can pick up indicative biomarkers for Alzheimer's disease. Aptamer agreed to use its Optimer binders technology, a next generation aptamer platform which finds application in therapeutic and diagnostic development.

Clinical Trial Analysis: Over 100 Trials are Evaluating Aptamers to Treat Myriad of Disease Indications

Over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity. Given the various advantages, aptamer-based therapeutics in the current pipeline are targeting a range of therapeutic areas, such as oncological disorders, ophthalmological disorders and metabolomic disorders.

Market Drivers: Technological Advancement in Aptamers Industry

In order to further enhance their performance, aptamers can be linked with various diagnostic agents, using physical or chemical conjugation. Moreover, to ensure the development of more effective therapy candidates, several players have developed novel aptamer-based technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment.

To support the various initiatives undertaken by industry players, investments worth over USD 1.3 billion have been reported in the past five years. In July 2023, UK based Aptamer Group successfully raised £3.6 million.

Aptamers Market Size Analysis: North America Holds the Largest Market Share

The global aptamers market is projected to reach $12.8 billion by 2035, growing at a high CAGR driven by anticipated approvals. North America emerged as the hub for aptamer companies engaged in development of aptamer therapeutics, with over 55% of the players established in the region. Currently, the only approved aptamer drug is also marketed in the US.

Key Companies in Aptamers Market Involved in Developing Therapeutics, Technologies or Services

Examples of key aptamers (which have also been profiled in this market report; the complete list of aptamers companies is available in the full report) include Ajinomoto Bio-Pharma Services, BioSpring, CliniSciences, CMIC Group, Halo-Bio RNAi Therapeutics, LGC Biosearch Technologies, NeoNeuro, New England Biolabs, Nitto Denko Avecia, NOXXON Pharma, RIBOMIC and SomaLogic. This market report includes an easily searchable excel database of all the aptamers companies, worldwide.

Aptamers Market Report Coverage

The aptamers market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:

  • A preface providing an introduction to the full report, Aptamers Market: Industry Trends and Global Forecasts, till 2035.
This image represents the overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics. Most of the aptamer drugs are being developed as RNA-based therapies; 46% of the aptamer-based therapies are in pre-clinical stage and are being developed for various therapeutic areas This image highlights the competitiveness analysis of aptamer-based service providers. In order to maintain a competitive edge, players are actively enhancing their existing offerings, both in terms of portfolio strength and diversity This image provides list of Aptamer-based Technology Providers. Nearly 50% of the aptamer-based technology providers are based in North America; most of the technologies are focused on drug discovery and development related applications
  • An outline of the systematic research methodology adopted to conduct the study on aptamers therapeutics, technologies or services providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An executive summary of the key insights captured during our research, offering a high-level view on the current landscape of the aptamers market and their likely evolution in the short to mid and long term.
  • A detailed overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics, along with information on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers, L-RNA aptamers and peptide aptamers), location of headquarters, phase of development (discovery, pre-clinical, clinical and approved), line of treatment (1st and 2nd line of treatment), mechanism of action, route of administration (intravenous, intravitreal and subcutaneous), type of therapy (monotherapy and combinational therapy)
  • Market landscape also covers analysis of the therapeutic area (bleeding disorders, bone disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders and ophthalmological disorders) and target indication (geographic atrophy, macular degeneration, stroke, acute stroke, ischemic stroke, multiple myeloma, chronic lymphocytic leukemia, metastatic pancreatic cancer and others).
  • A detailed overview of the current market landscape of players engaged in the development of aptamer-based technologies, based on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers and peptide aptamers), location of headquarters, status of development (concept, under development and commercialized), type of aptamer technology used (SELEX, NGS, ELISA and others), application area (research, diagnostic and therapeutic purposes), purpose of aptamer technology (Characterization, drug discovery, drug development, identification, biomarker discovery, assay, validation and others), type of analyte (serum, plasma, saliva and others), therapeutic area (autoimmune disorders, infectious disorders, neurodegenerative disorders, neurological disorders, antibiotic resistance, bone disorders, CNS disorders, genetic disorders, infectious diseases, nephrological disorders, oncological disorders, ophthalmological disorders, oral diseases and psychological disorders) and target indication (amyotrophic lateral sclerosis,  breast cancer ,  colon cancer,  dengue virus,  liver cancer,  prostate cancer, porcine reproductive and respiratory syndrome virus (PRRSv), mycoplasma hyopneumoniae,  stomach cancer and others).
  • A detailed overview of the current market landscape of aptamer-based service providers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service provider (contract research organizations, contract manufacturing organizations and third-party service providers), scale of operation (small, medium and large scale), area of application (therapeutic, diagnostic and others), type of aptamer technology used (ELISA, NGS, SELEX and others), type of aptamer technology platform (computational and others), and types of analysis offered (discovery, screening, characterization, synthesis, modification and purification).
  • A detailed competitiveness analysis of aptamer-based service providers, based on several relevant parameters, such as supplier strength (in terms of years of experience), portfolio strength (in terms of number of services offered) and portfolio diversity (based on scale of operation, area of application, aptamer technology used and types of analysis offered).
  • An insightful competitiveness analysis of aptamer-based technologies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on type of aptamer, status of development, area of application, type of aptamer technology used and purpose of aptamer technology).
  • An insightful product competitiveness analysis, benchmarking aptamer-based therapies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on phase of development, line of treatment, type of therapy, route of administration and target indication).
  • An analysis on the recent developments within the aptamers industry, highlighting information on several partnerships and collaborations that have been established in aptamers market, during the period 2016-2021.
This image highlights the analysis of the start-ups engaged in aptamers-based therapeutics domain. Start-ups are spearheading the innovation in this domain; our proprietary benchmarking analysis, based on a variety of parameters, highlights the leading players This image presents an in-depth analysis of patents related to aptamer-based therapies and technologies. Over the years, the intellectual capital related to the aptamer-based therapeutics and diagnostics has grown at a commendable pace; several patents have been filed by both industry and non-industry players This image provides list of Aptamer-based Service Providers. Specifically, service providers possess a range of reactors which can operate at different scales; ~40% of the small players are capable of supporting the production of aptamers for an array of applications
  • A detailed analysis of various investments made by players engaged in aptamers market, based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in aptamers market, during the period 2016-2021.
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects focused on aptamers, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
  • A detailed review of close to 390 peer-reviewed, scientific articles related to research on aptamers, based on several parameters, such as year of publication, type of publication, and popular keywords. The chapter also provides information on the top journals, top institutes and top authors (in terms of number of articles published).
  • An in-depth analysis of patents related to aptamer-based therapies and technologies, filed / granted since 2016, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players and regional distribution of trials.
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in aptamers market, based on several parameters, such as number of technologies offered, type of aptamer, status of development, area of application, type of aptamer technology used and purpose of aptamer technology.
  • Elaborate profiles of prominent players (shortlisted based our proprietary scoring criteria) engaged in aptamers market. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key executives. It also includes details on their respective product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent technologies (shortlisted based our proprietary scoring criteria) developed by players engaged in aptamers market. Each technology profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details on their respective technology portfolio, recent developments and an informed future outlook.
  • An informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics, taking into account the target patient population in ongoing and planned clinical trials focused on aptamer-based therapies, sponsored by both industry and non-industry players.
  • A detailed aptamers market forecast analysis in order to estimate the existing market size and future opportunity of the aptamers market. We have provided an informed estimate of the evolution of the market for the forecast period 2024-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of application area (therapeutics, research and diagnostics), type of aptamer (DNA, RNA and peptide), target indication (geographic atrophy, macular degeneration, Von Willebrand diseases, hemophilia A), route of administration (intravitreal, intravenous, subcutaneous), scale of operation (clinical and commercial), focus area (product development, product commercialization, technology integration, technology utilization and others), company size (very small, small, mid-sized, large and very large) and key geographical regions (North America, Europe, Asia-Pacific And Rest of the World)
This image highlights an informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics. The existing capacity is sufficient to meet the current global annual demand; we anticipate that players will continue to invest in building incremental capacity to meet the long-term expectations This image projects the estimated the future size of the aptamer-based therapies, technologies and services market. The global aptamer therapeutics market is expected to witness an annualized growth of 25% in coming few years; the opportunity is likely to be well distributed for different types of aptamers across various indications This image provides the market segment of the aptamer-based therapies, technologies and services market. The market for aptamer-based technologies is also anticipated to witness a steady growth; technologies focused on product development are expected to gain significant traction

 

Recent Developments in Aptamers Market

Several recent developments have taken place related to aptamers industry, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall aptamers market trends that have been outlined in our analysis.

  • In September 2023, Somalogic extended it 2021 partnership with Novo Nordisk till 2025. Using Somalogic's platform (which includes modified aptamers), Novo Nordisk will continue the drug development efforts in the field of NASH, diabetes and cardiovascular disorders.
  • In July 2023, Zentek and McMaster University announced the development of a novel aptamer technology platform with an increased aptamer binding affinity. The platform enhances the sensitivity of aptamer-based diagnostics for identifying different biomarkers.
  • In April 2023, researchers from the University of Toronto, Canada and Northwestern University, IL, USA developed a novel biosensor, utilizing DNA aptamers for the detection of disease biomarker in complex blood samples.

 

Frequently Asked Questions

Question 1: What are aptamers?

Answer: Aptamers refer to single-stranded, short DNA or RNA molecules which have affinity for a specific target, including proteins, peptides, carbohydrates and even live cells.

Question 2: How many aptamer therapeutics have been approved?

Answer: Two RNA aptamers have received FDA approval. The first aptamer, Macugen was discontinued. FDA approved the second RNA aptamer, Izervay, in August 2023.

Question 3: What is the global aptamers market size?

Answer: The aptamer therapeutics market size is estimated to be worth $451 million in 2024. Izervay was launched in the US market in 2023 and will be garnering sales in 2024.

Question 4: What is the projected aptamers market growth till 2035?

Answer: The global aptamer market is expected to grow at compounded annual growth rate (CAGR) of 36% during the forecast period 2024 - 2035.

Question 5: Who are the leading aptamer companies in the aptamers market?

Answer: Ajinomoto Bio-Pharma Services, BioSpring, CliniSciences, CMIC Group, Halo-Bio RNAi Therapeutics, LGC Biosearch Technologies, NeoNeuro, New England Biolabs, Nitto Denko Avecia, NOXXON Pharma, RIBOMIC and SomaLogic.

Question 6: How much money has been invested in the companies developing aptamer therapeutics in the aptamers industry?

Answer: Over the last few years, more than USD 1.3 billion has been invested in the companies developing aptamer therapeutics in aptamers market for R&D activities.

Question 7: How many aptamer therapeutics are currently being developed?

Answer: Presently, more than 50 aptamer therapeutics are being developed.

Question 8: Which region is the hub for aptamer companies engaged in development of aptamer therapeutics?

Answer: North America emerged as the hub for aptamer companies engaged in development of aptamer therapeutics, with over 55% of the players established in the region.

Question 9: How many aptamer technology are available?

Answer: More than 50 aptamer technology are available focused on drug discovery and development related applications.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com